Most pharma clinical operations run on a patchwork of CTMS, EDC, eTMF, Safety, RTSM, and eCOA systems bought at different times from different vendors. Teams spend hours reconciling data between them, re-entering the same information, and building reports by hand. Nobody has a single view of study progress, so problems surface late.
Most clinical leaders already know this costs them. The harder part is proving it: showing finance, IT, and leadership exactly what fragmentation costs today and what unification would return, in numbers they trust.
Key numbers
| Number |
What it means |
| 40% |
Reduction in study start-up time for an oncology-focused biotech after unifying CTMS, EDC, and eTMF |
| 50% |
Decrease in protocol deviation incidents at the same company |
| 25% |
Faster interim analysis delivery for a large sponsor running trials in 30+ countries |
| $500K–$1M |
Potential annual savings from eliminating redundant licenses and integration maintenance (sample ROI model) |
| 20–30% |
Potential reduction in FTE hours through automated scheduling, site activation, and eTMF filing |
| 7 days → 2 days |
Average query resolution time in the sample ROI model |
| 6–12 months |
When a well-implemented platform typically starts showing measurable improvements |
Who this is for
- Clinical operations leaders: Track the metrics that matter, from start-up cycle time and protocol deviations to recruitment and retention, in one place.
- Finance and procurement: Compare total cost of ownership for unified vs. multi-vendor setups, and see where savings come from over 3–5 years.
- IT and digital transformation teams: Understand why point-to-point integrations break down and what native integration changes for validation, upgrades, and support.
- Quality and regulatory teams: Measure audit readiness, query resolution, and submission timelines, and see how unification reduces inspection risk.
What's inside
- What a unified eClinical platform is, and how it differs from partial integrations
- Four measurement dimensions: operational, financial, compliance and quality, and data and decision metrics
- Real-world results from pharma sponsors that unified their platforms
- Before-and-after snapshots and industry benchmarks vs. legacy systems
- How AI, workflow automation, wearables, ePRO/eCOA, and real-world data fit in
- Organizational outcomes: collaboration, global scalability, and faster time to market
- Implementation considerations, including data migration and change management
- A sample ROI model and a TCO comparison with multi-vendor stacks
- What ICH E6(R3) means for the future of clinical operations
Why it matters now
ICH E6(R3) puts more weight on risk-based oversight, data integrity, and traceability, which is hard to show when your data lives in six systems. At the same time, trials are getting more complex, more global, and more decentralized, and every delay pushes back patient access and revenue. Budgets are tight, so investments need hard numbers behind them. This whitepaper gives you the framework to measure where you are and make the case for where you need to be.
Build the business case for unification, with real numbers. Get the metrics framework, benchmarks, and sample ROI model.
